ClinicalTrials.Veeva

Menu
U

University of Texas Health Science Center at Houston | McGovern Medical School - ACTAT - Research Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KRN23
GED-0301
Fluvoxamine
Hydrocortisone
Vigabatrin
Argatroban
Cisplatin
Cocaine
Glutamine
clindamycin

Parent organization

This site is a part of University of Texas Health Science Center at Houston

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 212 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and...

Enrolling
Hemophilia
Biological: Coagulation Factor VIIa (Recombinant)

Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patient...

Active, not recruiting
Acute Ischemic Stroke
Drug: Elezanumab
Drug: Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Pa...

Active, not recruiting
Vaso-occlusive Pain Episode in Sickle Cell Disease
Vaso-occlusive Crisis
Drug: Inclacumab

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Asundexian (BAY2433334)
Drug: Placebo

The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Set...

Enrolling
Stroke
Patent Foramen Ovale
Device: AMPLATZER™ PFO Occluder

This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a...

Active, not recruiting
COVID-19
Pulmonary Fibrosis
Drug: BIO 300 Oral Suspension
Drug: Placebo

The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZ...

Enrolling
Stroke
Patent Foramen Ovale
Device: Standard of Care PFO Closure Device
Device: Investigational PFO Closure Device

This study will evaluate the safety and effectiveness of the Edwards SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve (THV) compared with clinical s...

Active, not recruiting
Aortic Stenosis, Severe
Heart Diseases
Device: Edwards SAPIEN 3 / SAPIEN 3 Ultra THV

To demonstrate the safety and effectiveness of the Reducer system for treatment of patients with refractory angina pectoris treated with maximally to...

Enrolling
Refractory Angina
Other: Arm 2 (control): Implantation procedure with no device implanted
Device: Arm 3 (unblinded, non-randomized): Single arm registry

The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Exc...

Enrolling
Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Abdominal Aortic Aneurysm
Device: Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis
Device: Medtronic Endurant II or Endurant IIs Stent Graft System

This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions p...

Active, not recruiting
Ischemic Heart Disease
Coronary Artery Disease
Device: Orbital Atherectomy
Device: Balloon

The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of singl...

Enrolling
Phenylketonuria
Drug: Placebo Tablet
Drug: JNT-517 Suspension

The purpose of this clinical study is to assess the safety and effectiveness of the Atrial Flow Regulator in the treatment of subjects, 18 years of a...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure With Reduced Ejection Fraction (HFrEF)
Device: Atrial Flow Regulator
Device: Sham Comparator

This single-blind randomized control study will follow 142 subjects across 7 sites randomized on a 1:1 ratio to compare treatment efficacy and safety...

Active, not recruiting
Hiatal Hernia
GERD
Procedure: LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION

A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fis...

Enrolling
Kidney Disease, End-Stage
Arteriovenous Fistula
Device: EndoAVF Creation

Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plav...

Active, not recruiting
Heart Valve Disease
Device: On-X Valve with Standard warfarin Therapy
Device: On-X valve using reduced anticoagulation

The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nim...

Active, not recruiting
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Drug: GTX-104
Drug: Nimotop 30 MG Oral Capsule

Trial sponsors

N
The University of Texas System (UT) logo
S
Celgene logo
Duke University logo
Johns Hopkins University logo
Pfizer logo
M
Abbott logo
Kyowa Kirin logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems